Polpharma European CDMO Partner & API Manufacturer since 1951 Polpharma European CDMO Partner & API Manufacturer since 1951

X
[{"orgOrder":0,"company":"SFA Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"SFA Therapeutics Announces FDA Approval To Begin IND Trial","therapeuticArea":"Dermatology","highestDevelopmentStatus":"IND Enabling","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","url1":"","url2":"","graph1":"Small molecule","graph2":"SFA Therapeutics"},{"orgOrder":0,"company":"Kymera Therapeutics","sponsor":"Morgan Stanley","pharmaFlowCategory":"D","amount":"$100.0 million","upfrontCash":"Undisclosed","newsHeadline":"Preclinical Protein Degrader Biotech Kymera Therapeutics Files for A $100 Million Ipo","therapeuticArea":"Dermatology","highestDevelopmentStatus":"IND Enabling","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","url1":"","url2":"","graph1":"Small molecule","graph2":"Kymera Therapeutics"},{"orgOrder":0,"company":"Histogen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Histogen Announces Update for its HST-002 Dermal Filler Program","therapeuticArea":"Dermatology","highestDevelopmentStatus":"IND Enabling","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2020","url1":"","url2":"","graph1":"Large molecule","graph2":"Histogen"},{"orgOrder":0,"company":"Kymera Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kymera Therapeutics to Deliver Two Podium Presentations at 3rd Annual Targeted Protein Degradation Summit","therapeuticArea":"Dermatology","highestDevelopmentStatus":"IND Enabling","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","url1":"","url2":"","graph1":"Small molecule","graph2":"Kymera Therapeutics"},{"orgOrder":0,"company":"Kymera Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kymera Therapeutics to Present Interim Results from a Non-Interventional Study Characterizing IRAK4 Expression and Demonstrating Proof of Mechanism of an IRAK4 Degrader in Patients with Hidradenitis Suppurativa","therapeuticArea":"Dermatology","highestDevelopmentStatus":"IND Enabling","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","url1":"","url2":"","graph1":"Small molecule","graph2":"Kymera Therapeutics"},{"orgOrder":0,"company":"Numab Therapeutics","sponsor":"Kaken Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Numab Therapeutics and Kaken Pharmaceutical Form Co-Development Alliance for a Next-Generation Atopic Dermatitis Treatment Option","therapeuticArea":"Dermatology","highestDevelopmentStatus":"IND Enabling","country":"SWITZERLAND","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2021","url1":"","url2":"","graph1":"Large molecule","graph2":"Numab Therapeutics"},{"orgOrder":0,"company":"Kintor Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kintor\u2019s GT20029 IND for PROTAC AR Degrader Was Accepted by NMPA","therapeuticArea":"Dermatology","highestDevelopmentStatus":"IND Enabling","country":"CHINA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2021","url1":"","url2":"","graph1":"Small molecule","graph2":"Kintor Pharmaceutical"},{"orgOrder":0,"company":"Safety Shot","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Jupiter Wellness Advances Clinical Pipeline of CBD-Based Topical Treatments","therapeuticArea":"Dermatology","highestDevelopmentStatus":"IND Enabling","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"April 2021","url1":"","url2":"","graph1":"Small molecule","graph2":"Safety Shot"},{"orgOrder":0,"company":"Kintor Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kintor Pharmaceutical Receives IND Clearance by the U.S. FDA for GT20029 to Treat Androgenetic Alopecia and Acne","therapeuticArea":"Dermatology","highestDevelopmentStatus":"IND Enabling","country":"CHINA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2021","url1":"","url2":"","graph1":"Small molecule","graph2":"Kintor Pharmaceutical"},{"orgOrder":0,"company":"DICE Therapeutics","sponsor":"RA Capital Management","pharmaFlowCategory":"D","amount":"$60.0 million","upfrontCash":"Undisclosed","newsHeadline":"DiCE Molecules Announces $60 Million Series C-1 Financing","therapeuticArea":"Dermatology","highestDevelopmentStatus":"IND Enabling","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2021","url1":"","url2":"","graph1":"Small molecule","graph2":"DICE Therapeutics"},{"orgOrder":0,"company":"Safety Shot","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Jupiter Wellness Applies for IND Number from the US Food and Drug Administration","therapeuticArea":"Dermatology","highestDevelopmentStatus":"IND Enabling","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"August 2021","url1":"","url2":"","graph1":"Small molecule","graph2":"Safety Shot"},{"orgOrder":0,"company":"PolarityTE","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"PolarityTE Provides Update on Investigational New Drug Application","therapeuticArea":"Dermatology","highestDevelopmentStatus":"IND Enabling","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2021","url1":"","url2":"","graph1":"Large molecule","graph2":"PolarityTE"},{"orgOrder":0,"company":"Kintor Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kintor Pharma Receives IND Clearance by NMPA for KX-826\u2019s Pivotal Study to Treat Male Alopecia Patients","therapeuticArea":"Dermatology","highestDevelopmentStatus":"IND Enabling","country":"CHINA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2021","url1":"","url2":"","graph1":"Small molecule","graph2":"Kintor Pharmaceutical"},{"orgOrder":0,"company":"Novelty Nobility","sponsor":"ValenzaBio","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"ValenzaBio and Novelty Nobility Announce Exclusive License Agreement for Potential Best-in-Class Anti-c-KIT Monoclonal Antibody","therapeuticArea":"Dermatology","highestDevelopmentStatus":"IND Enabling","country":"SOUTH KOREA","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2022","url1":"","url2":"","graph1":"Large molecule","graph2":"Novelty Nobility"},{"orgOrder":0,"company":"Aquavit Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aquavit Files IND with FDA for DTX-021, a New Botulinum Toxin","therapeuticArea":"Dermatology","highestDevelopmentStatus":"IND Enabling","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2022","url1":"","url2":"","graph1":"Large molecule","graph2":"Aquavit Pharmaceuticals"},{"orgOrder":0,"company":"InnoCare Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"InnoCare Announces Approval of Clinical Trial of TYK2 JH2 Allosteric Inhibitor ICP-488 in China","therapeuticArea":"Dermatology","highestDevelopmentStatus":"IND Enabling","country":"CHINA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2022","url1":"","url2":"","graph1":"Small molecule","graph2":"InnoCare Pharma"},{"orgOrder":0,"company":"Lemonex Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lemonex Announces IND Approval for Phase 1 Clinical Trial of LEM-S401, siRNA Gene Therapeutics With Nano-Drug Delivery Platform DegradaBALL\u00ae","therapeuticArea":"Dermatology","highestDevelopmentStatus":"IND Enabling","country":"SOUTH KOREA","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2022","url1":"","url2":"","graph1":"Large molecule","graph2":"Lemonex Bio"},{"orgOrder":0,"company":"Lynk Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lynk Pharmaceuticals Announces IND Approval of LNK01004 for Atopic Dermatitis in China","therapeuticArea":"Dermatology","highestDevelopmentStatus":"IND Enabling","country":"CHINA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2022","url1":"","url2":"","graph1":"Small molecule","graph2":"Lynk Pharmaceuticals"},{"orgOrder":0,"company":"OrsoBio","sponsor":"Samsara BioCapital","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"OrsoBio Initiates IND-Enabling Activities for Liver-Targeted Mitochondrial Protonophore TLC-6740 for the Treatment of Severe Metabolic Disorders","therapeuticArea":"Dermatology","highestDevelopmentStatus":"IND Enabling","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2022","url1":"","url2":"","graph1":"Small molecule","graph2":"OrsoBio"},{"orgOrder":0,"company":"Brexogen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Brexogen's Exosome Therapy for Atopic Dermatitis, 'BRE-AD01' Accepted for Phase 1 Clinical Trials by US FDA","therapeuticArea":"Dermatology","highestDevelopmentStatus":"IND Enabling","country":"SOUTH KOREA","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"November 2022","url1":"","url2":"","graph1":"Cell and Gene therapy","graph2":"Brexogen"},{"orgOrder":0,"company":"Escient Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Escient Pharmaceuticals Announces IND Clearance by FDA to Start Phase 1 Study of EP262, a First-in-Class Oral MRGPRX2 Antagonist for Mast Cell Mediated Disorders","therapeuticArea":"Dermatology","highestDevelopmentStatus":"IND Enabling","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2023","url1":"","url2":"","graph1":"Small molecule","graph2":"Escient Pharmaceuticals"},{"orgOrder":0,"company":"Villaris Therapeutics","sponsor":"Incyte Corporation","pharmaFlowCategory":"D","amount":"$1,430.0 million","upfrontCash":"$70.0 million","newsHeadline":"Incyte Announces Agreement to Acquire Medicxi-Backed Villaris Therapeutics and Auremolimab (VM6), an Anti-IL-15R\u03b2 Monoclonal Antibody","therapeuticArea":"Dermatology","highestDevelopmentStatus":"IND Enabling","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2022","url1":"","url2":"","graph1":"Large molecule","graph2":"Villaris Therapeutics"},{"orgOrder":0,"company":"Allorion Therapeutics","sponsor":"INCE Capital","pharmaFlowCategory":"D","amount":"$50.0 million","upfrontCash":"Undisclosed","newsHeadline":"A Next-generation Precision Medicine Company Focusing On Oncology And Autoimmune Diseases, Raises $50 Million Series B Financing","therapeuticArea":"Dermatology","highestDevelopmentStatus":"IND Enabling","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2023","url1":"","url2":"","graph1":"Small molecule","graph2":"Allorion Therapeutics"},{"orgOrder":0,"company":"Aquavit Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aquavit Files Two IND's For Its Botulinum Toxin With FDA","therapeuticArea":"Dermatology","highestDevelopmentStatus":"IND Enabling","country":"U.S.A","productType":"Large molecule","productStatus":"Approved","date":"March 2023","url1":"","url2":"","graph1":"Large molecule","graph2":"Aquavit Pharmaceuticals"},{"orgOrder":0,"company":"OliX Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"OliX Pharmaceuticals Receives Regulatory Approval to Commence Phase 1 Clinical Trial of Treatment of Androgenic Alopecia","therapeuticArea":"Dermatology","highestDevelopmentStatus":"IND Enabling","country":"SOUTH KOREA","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2023","url1":"","url2":"","graph1":"Large molecule","graph2":"OliX Pharmaceutical"},{"orgOrder":0,"company":"OnQuality Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"OnQuality Announces FDA Clearance of IND Application for OQL036","therapeuticArea":"Dermatology","highestDevelopmentStatus":"IND Enabling","country":"CHINA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2023","url1":"","url2":"","graph1":"Small molecule","graph2":"OnQuality Pharma"},{"orgOrder":0,"company":"Aquavit Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aquavit Files Investigational New Drug Application for its Flagship Intradermal Injection of Botulinum Toxin","therapeuticArea":"Dermatology","highestDevelopmentStatus":"IND Enabling","country":"U.S.A","productType":"Large molecule","productStatus":"Approved","date":"April 2023","url1":"","url2":"","graph1":"Large molecule","graph2":"Aquavit Pharmaceuticals"},{"orgOrder":0,"company":"Reviva Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Reviva Pharmaceuticals Announces Intent to File an IND for Brilaroxazine in Psoriasis After Promising Preclinical Data","therapeuticArea":"Dermatology","highestDevelopmentStatus":"IND Enabling","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2023","url1":"","url2":"","graph1":"Small molecule","graph2":"Reviva Pharmaceuticals"},{"orgOrder":0,"company":"Accro Bioscience","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"TYK2\/JAK1 Inhibitor AC-201 of Accropeutics Bioscience gained Human Research Ethics Committees (HREC) permission for Phase I","therapeuticArea":"Dermatology","highestDevelopmentStatus":"IND Enabling","country":"CHINA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2023","url1":"","url2":"","graph1":"Small molecule","graph2":"Accro Bioscience"},{"orgOrder":0,"company":"TRexBio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"TRexBio Announces Development Candidate, TRB-061, a Novel TNFR2 Agonist for the Treatment of Inflammatory Diseases","therapeuticArea":"Dermatology","highestDevelopmentStatus":"IND Enabling","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"November 2023","url1":"","url2":"","graph1":"Cell and Gene therapy","graph2":"TRexBio"},{"orgOrder":0,"company":"VYNE Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"VYNE Therapeutics Reports Positive Results from Preclinical Models for Oral BD2-Selective BET Inhibitor VYN202","therapeuticArea":"Dermatology","highestDevelopmentStatus":"IND Enabling","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2023","url1":"","url2":"","graph1":"Small molecule","graph2":"VYNE Therapeutics"},{"orgOrder":0,"company":"OnQuality Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"OnQuality Announces FDA Clearance of IND Application for OQL025 for the treatment of EGFR Inhibitor-Induced Acneiform Rash","therapeuticArea":"Dermatology","highestDevelopmentStatus":"IND Enabling","country":"CHINA","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"January 2024","url1":"","url2":"","graph1":"Undisclosed","graph2":"OnQuality Pharma"},{"orgOrder":0,"company":"Guangzhou Fermion Technology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Fermion's TYK2 JH2 Inhibitor FZ007-119 Granted IND Approval by China NMPA","therapeuticArea":"Dermatology","highestDevelopmentStatus":"IND Enabling","country":"CHINA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2024","url1":"","url2":"","graph1":"Small molecule","graph2":"Guangzhou Fermion Technology"},{"orgOrder":0,"company":"Kymera Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kymera Therapeutics Presents Preclinical Data for STAT6 and TYK2 First-In-Class, Oral Degrader Immunology Programs at the American Academy of Dermatology Annual Meeting","therapeuticArea":"Dermatology","highestDevelopmentStatus":"IND Enabling","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2024","url1":"","url2":"","graph1":"Small molecule","graph2":"Kymera Therapeutics"},{"orgOrder":0,"company":"ARCA Biopharma","sponsor":"Oruka Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"ARCA biopharma and Oruka Therapeutics Announce Merger Agreement","therapeuticArea":"Dermatology","highestDevelopmentStatus":"IND Enabling","country":"UNITED KINGDOM","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2024","url1":"","url2":"","graph1":"Small molecule","graph2":"ARCA Biopharma"},{"orgOrder":0,"company":"Oruka Therapeutics","sponsor":"Fairmount","pharmaFlowCategory":"D","amount":"$275.0 million","upfrontCash":"Undisclosed","newsHeadline":"ARCA biopharma and Oruka Therapeutics Announce Merger Agreement","therapeuticArea":"Dermatology","highestDevelopmentStatus":"IND Enabling","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2024","url1":"","url2":"","graph1":"Small molecule","graph2":"Oruka Therapeutics"},{"orgOrder":0,"company":"Rubedo Life Sciences","sponsor":"Khosla Ventures","pharmaFlowCategory":"D","amount":"$40.0 million","upfrontCash":"Undisclosed","newsHeadline":"Rubedo Life Sciences Closes $40M Series A Financing Led by Khosla Ventures and Ahren Innovation Capital","therapeuticArea":"Dermatology","highestDevelopmentStatus":"IND Enabling","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2024","url1":"","url2":"","graph1":"Small molecule","graph2":"Rubedo Life Sciences"},{"orgOrder":0,"company":"Rubedo Life Sciences","sponsor":"Beiersdorf AG","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Rubedo Pulls in $40M Series A to Advance Atopic Dermatitis Candidate Targeting Aging Cells","therapeuticArea":"Dermatology","highestDevelopmentStatus":"IND Enabling","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2024","url1":"","url2":"","graph1":"Small molecule","graph2":"Rubedo Life Sciences"},{"orgOrder":0,"company":"AbCellera","sponsor":"Viking Global Investors","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"AbCellera, Viking Global Investors, and ArrowMark Partners Collaborate to Launch New Biotech Companies","therapeuticArea":"Dermatology","highestDevelopmentStatus":"IND Enabling","country":"CANADA","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2024","url1":"","url2":"","graph1":"Large molecule","graph2":"AbCellera"},{"orgOrder":0,"company":"VYNE Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"VYNE Therapeutics Announces FDA Clearance of IND Application for VYN202, a Novel BD2-Selective BET Inhibitor","therapeuticArea":"Dermatology","highestDevelopmentStatus":"IND Enabling","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2024","url1":"","url2":"","graph1":"Small molecule","graph2":"VYNE Therapeutics"}]

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Loading...
Filters Filter
×
FILTER:
filter Company
    filter Sponsor
      filter Country
        filter Product Type
          filter News Type

            Active Filter(s):

            Product Type

            Companies

            Details:

            VYN202 is a potential best-in-class oral small molecule BD2-Selective BET inhibitor recently got IND approval by FDA for the treatment of psoriasis and rheumatoid arthritis.

            Lead Product(s): VYN202

            Therapeutic Area: Dermatology Product Name: VYN202

            Highest Development Status: IND Enabling Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable May 06, 2024

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            Under the collaboration, AbCellera will advance the clinical program to develop the monoclonal antibody candidate ABCL575 for the treatment of Atopic dermatitis.

            Lead Product(s): ABCL575

            Therapeutic Area: Dermatology Product Name: ABCL575

            Highest Development Status: IND Enabling Product Type: Large molecule

            Partner/Sponsor/Collaborator: Viking Global Investors

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Collaboration May 01, 2024

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            The funding will be utilized to progress the company’s primary candidate, RLS-1496, for treating patients with atopic dermatitis and chronic psoriasis.

            Lead Product(s): RLS-1496

            Therapeutic Area: Dermatology Product Name: RLS-1496

            Highest Development Status: IND Enabling Product Type: Small molecule

            Partner/Sponsor/Collaborator: Khosla Ventures

            Deal Size: $40.0 million Upfront Cash: Undisclosed

            Deal Type: Series A Financing April 22, 2024

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            The financing will be utilized to fund the progress of the company’s primary candidate, RLS-1496, for treating patients with atopic dermatitis and chronic psoriasis.

            Lead Product(s): RLS-1496

            Therapeutic Area: Dermatology Product Name: RLS-1496

            Highest Development Status: IND Enabling Product Type: Small molecule

            Partner/Sponsor/Collaborator: Beiersdorf AG

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Partnership April 22, 2024

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            Through the merger, the company will focus on advancing Oruka’s pipeline of potentially best-in-class biologics, including ORKA-001 (an IL-23p19 inhibitor) for the treatment of plaque psoriasis.

            Lead Product(s): ORKA-001

            Therapeutic Area: Dermatology Product Name: ORKA-001

            Highest Development Status: IND Enabling Product Type: Small molecule

            Partner/Sponsor/Collaborator: Oruka Therapeutics

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Merger April 03, 2024

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            The net proceeds will be used to advance Oruka’s pipeline of potentially best-in-class biologics, including ORKA-001 (an IL-23p19 inhibitor) for the treatment of plaque psoriasis.

            Lead Product(s): ORKA-001

            Therapeutic Area: Dermatology Product Name: ORKA-001

            Highest Development Status: IND Enabling Product Type: Small molecule

            Partner/Sponsor/Collaborator: Fairmount

            Deal Size: $275.0 million Upfront Cash: Undisclosed

            Deal Type: Private Placement April 03, 2024

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            KT-621 is a once daily, oral STAT6 degrader with a potential biologics-like efficacy profile, to address multiple diseases including atopic dermatitis, asthma, and chronic obstructive pulmonary disorder, among others.

            Lead Product(s): KT-621

            Therapeutic Area: Dermatology Product Name: KT-621

            Highest Development Status: IND Enabling Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable March 08, 2024

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            FZ007-119 is a third-generation JAK inhibitor targeting TYK2 JH2. It's IND application is approved after preclinical studies for the treatment of plaque psoriasis, inflammatory bowel disease & rheumatoid arthritis

            Lead Product(s): FZ007-119

            Therapeutic Area: Dermatology Product Name: FZ007-119

            Highest Development Status: IND Enabling Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable February 05, 2024

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            OQL025 is a first-in disease topical agent to treat moderate to severe acneiform rash in patients receiving EGFR inhibitors. It works by selectively targeting the key pathways that lead to EGFR inhibitor-induced rash.

            Lead Product(s): OQL025

            Therapeutic Area: Dermatology Product Name: OQL025

            Highest Development Status: IND Enabling Product Type: Undisclosed

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable January 04, 2024

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            TRB-061, an agonist targeting TNF receptor 2 (TNFR2). TRB-061 expands regulatory T cells (Tregs) to restore homeostasis in the tissue at the site of inflammation.

            Lead Product(s): TRB-061

            Therapeutic Area: Dermatology Product Name: TRB-061

            Highest Development Status: IND Enabling Product Type: Cell and Gene therapy

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable November 14, 2023

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity
            Post Enquiry
            POST ENQUIRY